NOACs, AF, and PCI: What Do the Latest Data Suggest?

Slides:



Advertisements
Similar presentations
EXAMINATION Objective Assess the safety and performance of a new-generation DES vs. a BMS in the setting of primary PCI for treatment of patients with.
Advertisements

Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction STRATEGY Trial Journal of the American Medical.
Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial HORIZONS Trial.
Nick Alp Milton Keynes Hospital NHS FT Oxford Radcliffe NHS Trust Bleeding risks in the major trials – It does matter.
TLR Funnel plot (according to outcomes) for studies included in the meta-analysis Death A TVR B MACE DC SE(log OR)
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
When should aspirin be dropped from triple therapy?
Addressing the Challenges in Primary and Secondary Stroke Prevention
Polypharmacy Anticoagulation: AF meets PCI
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.
Covering the Bases in Cardioversion
European and US Guidelines
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
(p < for group 1 or 2 vs. group 3)
Learning Objectives. Learning Objectives Variable Response to Clopidogrel.
Atrial Fibrillation and PCI
Anticoagulants in Interventional Cardiology:
Updates in Anticoagulation: What Did We Learn From ESC 2017?
US Guidelines US Guidelines Low-risk Patients.
Achieving Long-Term Protection Post-MI
When Is Adding Aspirin to NOACs Worth the Risk?
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Access to NOAC Therapy:
NOACs in Clinical Practice: Are They All the Same?
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
A New Era for NOACs:.
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
Anticoagulation Highlights From the American Heart Association Meeting 2017.
New Perspectives in AF and PCI: Implications for the Practicing Physician.
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
New Perspectives in CAD and PAD: Weighing the Latest Evidence
Oral Anticoagulants in AFa,b A Brief History.
How and When to Decide on Revascularization in Stable Ischemic Heart Disease.
Selecting NOACs for High-Risk Patients
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.
Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:
NOACS: Emerging data in ACS/IHD
AF and PCI in Practice.
Access to NOAC Therapy:
TAVR and the Risk of Thrombosis
Late Breaking Clinical Trials
Understanding PAD.
What Anticoagulant Registries Are Revealing
Watching for the Patient With AF: Latest Advances and Technologies
A Better Solution For Cancer Patients With VTE?
VTE in Cancer.
ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.
Figure 2 Ischaemic and bleeding outcomes in the major clinical trials
Atrial Fibrillation.
Anticoagulation and Thrombosis Management
Identifying High-Risk AF Patients
Cancer-Associated Thrombosis
Antithrombotic Therapy in PAD
Updates in Anticoagulation: Key Sessions at ESC 2017
Antithrombotics in Arterial Disease: Focus on Coronary Disease
Elevated Admission Plasma Glucose Following ACS
The Challenge of AF and PCI: Practical Strategies to Improve Outcomes
Factor Xa Inhibitors in Coronary Artery Disease
Improving Adherence to Antiplatelet Therapy After an ACS Event
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
Primary safety endpoint
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.
Extraordinary Cases in Stroke Prevention
Antithrombotic Therapy in AF Patients Undergoing PCI
What's New in NOACs in AF?.
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

NOACs, AF, and PCI: What Do the Latest Data Suggest?

NOACs for Patients With AF

Case: Patient With STEMI

Case: Management of Antithrombotic Therapy in the Acute Setting

Case: Management of Postdischarge Antithrombotic Therapy

Triple Therapy: Factors to Consider

Antithrombotic Management of Patients With AF Undergoing PCI

Danish Registry Study of Patients With AF Risk of Bleeding With Antithrombotic Therapy

Danish Registry Study of Patients With MI Risk of Bleeding With Antithrombotic Therapy

Danish Registry Study of Patients With MI Annual Incidence of Bleeding

WOEST Trial Study Design

WOEST Trial Bleeding Events

WOEST Trial Death, MI, Stroke, Target-Vessel Revascularization, and Stent Thrombosis

PIONEER AF-PCI Study Design

PIONEER AF-PCI Clinically Significant Bleeding

PIONEER AF-PCI ISTH and GUSTO Bleeding

PIONEER AF-PCI MACE (All Participants)

PIONEER AF-PCI All-Cause Rehospitalization

Implications of PIONEER Antithrombotic Therapy Postdischarge

Ongoing Antithrombotic Trials With NOACs

Summary

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.